Halozyme Therapeutics: Royalty King
Source: SeekingAlpha
2026-05-19 22:33:53 ET
Investment Thesis
I started following Halozyme Therapeutics, Inc. ( HALO ) in August 2024, and the company continues to deliver value to shareholders while growing a stream of royalty payments at a significant pace. They recently released their 2026 Q1 earnings, where they outlined a ramp of shareholder creation and cash flow through 2030....
Read the full article on Seeking Alpha
For further details see:
Halozyme Therapeutics: Royalty King
Halozyme Therapeutics Inc.
NASDAQ: HALO
HALO Trading
5.02% G/L:
$69.58 Last:
703,086 Volume:
$66 Open:
HALO Latest News
May 11, 2026 04:01:00 pm
HALOZYME REPORTS FIRST QUARTER 2026 RESULTS AND REITERATES 2026 FINANCIAL GUIDANCE
HALO Stock Data
$9,572,395,800
114,186,687
0.24%
276
N/A
Biotechnology & Life Sciences
Healthcare
US
San Diego
